Image source: Shutterstock

Highlights

  • FDA Approval Granted: VYVGART® Hytrulo prefilled syringe approved for self-injection by adults with gMG and CIDP.

  • Patient Convenience Enhanced: The treatment can now be self-administered in 20–30 seconds at home or with caregiver assistance.

  • Backed by Clinical Data: Approval supported by bioequivalence and usability studies in patients and caregivers.

The U.S. Food and Drug Administration (FDA) has approved the VYVGART® Hytrulo prefilled syringe for self-injection, offering a new level of convenience and autonomy for adult patients diagnosed with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive, as well as those with chronic inflammatory demyelinating polyneuropathy (CIDP).

This next-generation delivery method of efgartigimod alfa and hyaluronidase-qvfc enables patients or their caregivers to administer treatment subcutaneously at home in as little as 20 to 30 seconds, following appropriate instruction. Healthcare professionals may also perform the injection, but the new option significantly broadens access and independence for patients managing these rare autoimmune conditions.

Developed under argenx’s strategic partnership with Halozyme, the prefilled syringe leverages the proprietary ENHANZE® drug delivery technology, which facilitates the rapid and high-volume administration of biologic therapies. This technology plays a central role in transforming complex treatments into more patient-friendly formats.

The FDA’s approval was informed by comprehensive data, including studies showing bioequivalence between the prefilled syringe and the previously approved VYVGART® Hytrulo in vial form. Additionally, human factors validation studies confirmed that patients with gMG or CIDP—and their caregivers—could safely and successfully handle and administer the medication using the prefilled syringe.

“Today’s approval represents a major milestone in improving quality of life for people living with gMG and CIDP,” said a spokesperson from argenx. “By enabling patients to self-administer VYVGART® Hytrulo, we are advancing our commitment to convenient, personalized treatment experiences.”

The original FDA approvals of VYVGART® Hytrulo for both gMG and CIDP were based on robust results from global Phase 3 clinical trials, including the ADAPT, ADAPT-SC, and ADHERE studies. These trials confirmed the efficacy and safety of the treatment in reducing disease burden and improving muscle strength and functionality in affected patients.